Ify Osunkwo
Chief Patient Officer, Rare Disease Novo Nordisk
Ifeyinwa (Ify) Osunkwo, MD, MPH is the chief patient officer at Novo Nordisk Rare Disease. Prior to this, she served as the inaugural chief patient officer and senior vice president at Forma Therapeutics. She has extensive experience in clinical management, population health, and health literacy and is an internationally acclaimed expert in sickle cell disease, health equity, and the management of chronic pain. At Novo Nordisk, Dr Osunkwo is responsible for realising the vision to transform the lives of patients living with rare diseases by improving access to care and clinical outcomes through value-based partnerships with global patient and community stakeholders while driving an internal culture of patient-centric treatment solution development. Before joining industry, Dr Ify Osunkwo spent 30 years as a lifespan haematologist, principal investigator and clinical trialist both in the US and Africa.
A dual national of US and Nigeria, Dr Ify holds an MD from The University of Nigeria, an MPH from Johns Hopkins University, Baltimore MD (USA) and is board-certified in paediatric haematology and oncology.
Seminars
Sustaining patient engagement measurement across multi-year programs is increasingly difficult as teams shrink, roles evolve, and priorities shift. This interactive workshop focuses on how to protect measurement continuity, credibility, and impact through organizational change – combining cross-functional systems thinking with practical strategies for adapting when resources are constrained. Participants will explore how to align stakeholders, leverage existing tools, and evolve their approach without losing momentum or trust.
This Workshop Will Gather Experts to Discuss:
- Designing cross-functional processes that sustain measurement across departments and long-term trials
- Leveraging existing technology and systems to capture engagement metrics efficiently
- Maintaining shared accountability across patient advocacy, clinical, medical, and commercial teams
- Prioritizing meaningful, defensible metrics that demonstrate impact on patient experience and trial outcomes
- Adapting measurement approaches during organizational change, budget pressure, or shifting priorities
